Loading...

Fluidigm

Nasdaq:FLDM
Snowflake Description

Flawless balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FLDM
Nasdaq
$855M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
FLDM Share Price and Events
7 Day Returns
2.5%
NasdaqGS:FLDM
1.2%
US Life Sciences
0.1%
US Market
1 Year Returns
124.5%
NasdaqGS:FLDM
23.3%
US Life Sciences
1.2%
US Market
FLDM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fluidigm (FLDM) 2.5% 2.1% -13.3% 124.5% 28.4% -57.5%
US Life Sciences 1.2% 8.4% 2.6% 23.3% 92.3% 110.9%
US Market 0.1% 0.6% 0.9% 1.2% 36.7% 37.9%
1 Year Return vs Industry and Market
  • FLDM outperformed the Life Sciences industry which returned 23.3% over the past year.
  • FLDM outperformed the Market in United States of America which returned 1.2% over the past year.
Price Volatility
FLDM
Industry
5yr Volatility vs Market

Value

 Is Fluidigm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Fluidigm to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Fluidigm.

NasdaqGS:FLDM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:FLDM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 0.99
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.989 (1 + (1- 21%) (6.86%))
1.029
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.029 * 5.96%)
8.86%

Discounted Cash Flow Calculation for NasdaqGS:FLDM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Fluidigm is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:FLDM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.86%)
2019 -51.90 Analyst x1 -47.68
2020 -34.20 Analyst x1 -28.86
2021 -16.80 Analyst x1 -13.02
2022 7.80 Analyst x1 5.55
2023 11.74 Est @ 50.51% 7.68
2024 15.99 Est @ 36.18% 9.61
2025 20.17 Est @ 26.14% 11.13
2026 24.02 Est @ 19.12% 12.18
2027 27.43 Est @ 14.2% 12.78
2028 30.39 Est @ 10.76% 13.00
Present value of next 10 years cash flows $-17.63
NasdaqGS:FLDM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $30.39 × (1 + 2.73%) ÷ (8.86% – 2.73%)
$509.08
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $509.08 ÷ (1 + 8.86%)10
$217.79
NasdaqGS:FLDM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-17.63 + $217.79
$200.15
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $200.15 / 69.02
$2.9
NasdaqGS:FLDM Discount to Share Price
Calculation Result
Value per share (USD) From above. $2.90
Current discount Discount to share price of $12.39
= -1 x ($12.39 - $2.90) / $2.90
-327.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Fluidigm is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fluidigm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fluidigm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:FLDM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.60
NasdaqGS:FLDM Share Price ** NasdaqGS (2019-06-18) in USD $12.39
United States of America Life Sciences Industry PE Ratio Median Figure of 21 Publicly-Listed Life Sciences Companies 37.34x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fluidigm.

NasdaqGS:FLDM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FLDM Share Price ÷ EPS (both in USD)

= 12.39 ÷ -1.60

-7.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fluidigm is loss making, we can't compare its value to the US Life Sciences industry average.
  • Fluidigm is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Fluidigm's expected growth come at a high price?
Raw Data
NasdaqGS:FLDM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
22.3%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 2.55x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fluidigm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fluidigm's assets?
Raw Data
NasdaqGS:FLDM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.64
NasdaqGS:FLDM Share Price * NasdaqGS (2019-06-18) in USD $12.39
United States of America Life Sciences Industry PB Ratio Median Figure of 38 Publicly-Listed Life Sciences Companies 4.64x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:FLDM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FLDM Share Price ÷ Book Value per Share (both in USD)

= 12.39 ÷ 2.64

4.69x

* Primary Listing of Fluidigm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fluidigm is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Fluidigm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Fluidigm has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Fluidigm expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fluidigm expected to grow at an attractive rate?
  • Unable to compare Fluidigm's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Fluidigm's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Fluidigm's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:FLDM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:FLDM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 22.3%
NasdaqGS:FLDM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 11.3%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.2%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:FLDM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:FLDM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 196 -35 1
2022-12-31 183 6 -25 2
2021-12-31 165 -19 -35 3
2020-12-31 144 -35 -44 5
2019-12-31 128 -44 -62 5
NasdaqGS:FLDM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 118 -29 -71
2018-12-31 113 -25 -59
2018-09-30 108 -24 -55
2018-06-30 104 -28 -56
2018-03-31 102 -32 -57
2017-12-31 102 -24 -61
2017-09-30 99 -35 -68
2017-06-30 97 -41 -72
2017-03-31 101 -40 -73
2016-12-31 104 -39 -76
2016-09-30 110 -33 -71
2016-06-30 117 -32 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Fluidigm is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Fluidigm's revenue is expected to grow by 11.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:FLDM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Fluidigm Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:FLDM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.58 -0.58 -0.58 1.00
2022-12-31 -0.71 -0.71 -0.71 1.00
2021-12-31 -0.42 -0.38 -0.47 2.00
2020-12-31 -0.68 -0.54 -0.91 5.00
2019-12-31 -0.99 -0.84 -1.22 5.00
NasdaqGS:FLDM Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.60
2018-12-31 -1.49
2018-09-30 -1.40
2018-06-30 -1.48
2018-03-31 -1.60
2017-12-31 -1.84
2017-09-30 -2.22
2017-06-30 -2.45
2017-03-31 -2.52
2016-12-31 -2.62
2016-09-30 -2.46
2016-06-30 -2.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fluidigm will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Fluidigm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fluidigm has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Fluidigm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fluidigm's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fluidigm does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fluidigm's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fluidigm's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Fluidigm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fluidigm Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:FLDM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 117.83 -71.23 83.80 31.15
2018-12-31 112.96 -59.01 79.78 30.03
2018-09-30 108.38 -54.70 73.68 38.08
2018-06-30 104.17 -55.89 73.76 38.08
2018-03-31 101.65 -56.58 75.75 38.08
2017-12-31 101.94 -60.54 79.52 30.83
2017-09-30 99.28 -67.77 86.42
2017-06-30 96.72 -71.62 87.44
2017-03-31 100.98 -73.30 90.31
2016-12-31 104.45 -75.99 93.21 38.42
2016-09-30 110.08 -71.17 92.53
2016-06-30 116.54 -60.65 90.96
2016-03-31 116.99 -57.27 88.34
2015-12-31 114.71 -53.32 82.96
2015-09-30 117.48 -51.38 78.41
2015-06-30 118.47 -55.90 78.53
2015-03-31 117.46 -53.35 75.16
2014-12-31 116.46 -52.83 71.32
2014-09-30 103.85 -46.53 66.06
2014-06-30 92.50 -37.03 58.48
2014-03-31 82.37 -28.39 52.22
2013-12-31 71.18 -16.53 48.41
2013-09-30 65.96 -15.49 45.39
2013-06-30 60.46 -15.35 42.40
2013-03-31 55.92 -15.89 40.22
2012-12-31 52.33 -19.02 38.48
2012-09-30 49.67 -18.88 35.89
2012-06-30 47.49 -19.22 34.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fluidigm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fluidigm has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fluidigm improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fluidigm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fluidigm has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Fluidigm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fluidigm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fluidigm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fluidigm's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fluidigm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fluidigm Company Filings, last reported 2 months ago.

NasdaqGS:FLDM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 182.25 58.69 75.13
2018-12-31 72.12 172.06 95.40
2018-09-30 22.41 169.35 35.83
2018-06-30 34.83 166.76 40.42
2018-03-31 48.57 164.16 47.25
2017-12-31 30.94 195.24 63.14
2017-09-30 39.07 195.17 62.37
2017-06-30 23.94 195.09 42.03
2017-03-31 38.50 195.02 50.28
2016-12-31 53.23 194.95 59.43
2016-09-30 67.97 194.88 71.25
2016-06-30 84.26 194.81 86.41
2016-03-31 98.98 194.74 95.22
2015-12-31 114.90 194.67 94.97
2015-09-30 124.13 195.63 97.07
2015-06-30 133.22 195.57 99.93
2015-03-31 142.45 195.51 116.41
2014-12-31 150.42 195.46 115.30
2014-09-30 154.56 195.40 95.26
2014-06-30 161.83 195.34 94.74
2014-03-31 167.43 195.25 143.15
2013-12-31 96.41 0.00 84.34
2013-09-30 97.01 0.00 63.68
2013-06-30 98.39 0.00 60.43
2013-03-31 100.12 0.00 79.57
2012-12-31 100.66 0.00 80.01
2012-09-30 102.66 1.88 86.16
2012-06-30 48.92 4.70 37.87
  • Fluidigm's level of debt (27.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (116.7% vs 27.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fluidigm has sufficient cash runway for 2.5 years based on current free cash flow.
  • Fluidigm has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -20.8% each year.
X
Financial health checks
We assess Fluidigm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fluidigm has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Fluidigm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fluidigm dividends. Estimated to be 0% next year.
If you bought $2,000 of Fluidigm shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fluidigm's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fluidigm's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:FLDM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:FLDM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fluidigm has not reported any payouts.
  • Unable to verify if Fluidigm's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fluidigm's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fluidigm has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Fluidigm's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Fluidigm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fluidigm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fluidigm has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Fluidigm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Linthwaite
COMPENSATION $2,585,208
AGE 45
TENURE AS CEO 2.7 years
CEO Bio

Mr. Stephen Christopher Linthwaite, also known as Chris, has been the President of Fluidigm Corporation since August 4, 2016. Mr. Linthwaite has been the Chief Executive Officer of Fluidigm Corporation since October 19, 2016. Mr. Linthwaite served as Chief Operating Officer of Fluidigm Corporation since August 4, 2016 until October 28, 2016. Mr. Linthwaite served as President of the Genetic Sciences Division at Thermo Fisher Scientific and the President of the BioProduction Division at Life Technologies. From August 2003 to April 2016, Mr. Linthwaite held various managerial positions at Thermo Fisher Scientific Inc., a life sciences company, and prior to its acquisition by Thermo Fisher, at Life Technologies Corporation, a life sciences company, including president, genetic sciences division, from December 2014 to April 2016, president, genetic analysis platform, from September 2011 to December 2014, and various other managerial positions at Invitrogen prior to the creation of Life Technologies through a merger of Invitrogen and Applied Biosystems. Prior to joining Invitrogen, Mr. Linthwaite held various strategic consulting roles. Mr. Linthwaite served on the board of directors of Claritas Genomics, Inc. from December 2014 to April 2016. He has been a Director of Fluidigm Corporation since October 19, 2016. Mr. Linthwaite received a M.B.A. from the University of Virginia (Darden) School of Business and a B.A. in Foreign Affairs from the University of Virginia. Prior to business school, Mr. Linthwaite served on active duty in the U.S. Army as an armor officer.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Fluidigm management team in years:

2.7
Average Tenure
44.5
Average Age
  • The tenure for the Fluidigm management team is about average.
Management Team

Chris Linthwaite

TITLE
President
COMPENSATION
$3M
AGE
45
TENURE
2.7 yrs

Vikram Jog

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$1M
AGE
62
TENURE
11.3 yrs

Brad Kreger

TITLE
Senior Vice President of Global Operations
COMPENSATION
$1M
AGE
43
TENURE
1.2 yrs

Nick Khadder

TITLE
Senior VP
COMPENSATION
$1M
AGE
44
TENURE
3 yrs

Steve Quake

TITLE
Co-Founder & Chairman of Advisory Board
TENURE
20.4 yrs

Andrew Quong

TITLE
Chief Science Officer

Agnes Lee

TITLE
Vice President of Investor Relations

Mark Spearman

TITLE
Senior Director of Corporate Communications

Angela Peters

TITLE
Vice President of Global Human Resources
TENURE
1.9 yrs

Colin McCracken

TITLE
Chief Commercial Officer
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Fluidigm board of directors in years:

12.5
Average Tenure
62
Average Age
  • The average tenure for the Fluidigm board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Sam Colella

TITLE
Chairman of the Board
COMPENSATION
$165K
AGE
78
TENURE
18.9 yrs

Chris Linthwaite

TITLE
President
COMPENSATION
$3M
AGE
45
TENURE
2.7 yrs

Steve Quake

TITLE
Co-Founder & Chairman of Advisory Board

Pat Jones

TITLE
Director
COMPENSATION
$128K
AGE
74
TENURE
8.3 yrs

Gary Burbach

TITLE
Director
COMPENSATION
$133K
AGE
56
TENURE
6.4 yrs

Richard Zare

TITLE
Member of Advisory Board
TENURE
18.5 yrs

Howard Shapiro

TITLE
Member of Advisory Board
TENURE
19.5 yrs

James Berger

TITLE
Member of Advisory Board
TENURE
17 yrs

Frank McCormick

TITLE
Member of Advisory Board
AGE
68
TENURE
12.5 yrs

Nicolas Barthelemy

TITLE
Director
COMPENSATION
$125K
AGE
52
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
26. Dec 18 Buy Levin Capital Strategies, L.P. Company 20. Dec 18 24. Dec 18 661 $7.79 $4,935
20. Dec 18 Buy Levin Capital Strategies, L.P. Company 18. Dec 18 19. Dec 18 164 $7.86 $1,284
18. Dec 18 Buy Levin Capital Strategies, L.P. Company 14. Dec 18 14. Dec 18 41 $7.81 $320
14. Dec 18 Buy Levin Capital Strategies, L.P. Company 12. Dec 18 12. Dec 18 1,000,000 $6.75 $6,750,000
11. Dec 18 Buy Levin Capital Strategies, L.P. Company 07. Dec 18 10. Dec 18 35,033 $7.95 $270,462
16. Nov 18 Buy Levin Capital Strategies, L.P. Company 14. Nov 18 14. Nov 18 47,768 $7.55 $360,696
13. Nov 18 Buy Levin Capital Strategies, L.P. Company 08. Nov 18 08. Nov 18 127 $7.84 $996
08. Nov 18 Buy Levin Capital Strategies, L.P. Company 06. Nov 18 06. Nov 18 855 $7.40 $6,326
26. Oct 18 Buy Levin Capital Strategies, L.P. Company 25. Oct 18 26. Oct 18 9,962 $7.21 $71,775
23. Oct 18 Buy Levin Capital Strategies, L.P. Company 19. Oct 18 19. Oct 18 25,209 $7.51 $189,231
15. Oct 18 Buy Levin Capital Strategies, L.P. Company 11. Oct 18 12. Oct 18 71 $7.45 $528
11. Oct 18 Buy Levin Capital Strategies, L.P. Company 09. Oct 18 09. Oct 18 34,896 $7.29 $254,217
03. Oct 18 Buy Levin Capital Strategies, L.P. Company 01. Oct 18 01. Oct 18 24 $7.56 $181
01. Oct 18 Buy Levin Capital Strategies, L.P. Company 27. Sep 18 27. Sep 18 52 $7.53 $392
27. Sep 18 Buy Levin Capital Strategies, L.P. Company 25. Sep 18 25. Sep 18 2,940 $7.98 $23,447
21. Sep 18 Buy Levin Capital Strategies, L.P. Company 19. Sep 18 19. Sep 18 40 $8.22 $329
13. Sep 18 Buy Levin Capital Strategies, L.P. Company 11. Sep 18 11. Sep 18 17 $8.42 $143
07. Sep 18 Buy Levin Capital Strategies, L.P. Company 05. Sep 18 06. Sep 18 201 $7.85 $1,577
04. Sep 18 Buy Levin Capital Strategies, L.P. Company 30. Aug 18 30. Aug 18 18 $7.86 $141
17. Aug 18 Buy Levin Capital Strategies, L.P. Company 15. Aug 18 15. Aug 18 25,500 $6.78 $172,880
10. Aug 18 Buy Levin Capital Strategies, L.P. Company 08. Aug 18 08. Aug 18 21 $6.76 $142
06. Aug 18 Buy Levin Capital Strategies, L.P. Company 02. Aug 18 02. Aug 18 29 $6.36 $184
02. Aug 18 Buy Levin Capital Strategies, L.P. Company 31. Jul 18 31. Jul 18 2,692 $6.41 $17,230
31. Jul 18 Buy Levin Capital Strategies, L.P. Company 27. Jul 18 27. Jul 18 20,029 $6.22 $123,071
16. Jul 18 Buy Levin Capital Strategies, L.P. Company 12. Jul 18 12. Jul 18 54 $6.27 $339
06. Jul 18 Buy Levin Capital Strategies, L.P. Company 22. Jun 18 03. Jul 18 95 $6.00 $551
X
Management checks
We assess Fluidigm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fluidigm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Changing Sentiment Drive Fluidigm's Share Price Down A Painful 77%?

Fluidigm isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't make profits, we'd generally expect to see good revenue growth. … That's not a very high growth rate considering it doesn't make profits.

Simply Wall St -

Can We See Significant Institutional Ownership On The Fluidigm Corporation (NASDAQ:FLDM) Share Register?

If you want to know who really controls Fluidigm Corporation (NASDAQ:FLDM), then you'll have to look at the makeup of its share registry. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Fluidigm is a smaller company with a market capitalization of US$379m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Fluidigm Corporation (NASDAQ:FLDM): What Are The Future Prospects?

In March 2018, Fluidigm Corporation (NASDAQ:FLDM) announced its earnings update. … with earnings expected to grow by 0.44% in the upcoming year … the past 5-year average growth rate of -21.01%

Simply Wall St -

Is Fluidigm Corporation's (NASDAQ:FLDM) Balance Sheet A Threat To Its Future?

While small-cap stocks, such as Fluidigm Corporation (NASDAQ:FLDM) with its market cap of US$220.27m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

When Will Fluidigm Corporation (NASDAQ:FLDM) Turn A Profit?

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. … The US$196.53m market-cap posted a loss in its most recent financial year of -US$60.53m and a latest trailing-twelve-month loss of -US$56.58m shrinking the gap between loss and breakeven? … Expectation from Life Sciences analysts is FLDM is on the verge of breakeven.

Simply Wall St -

Is There Now An Opportunity In Fluidigm Corporation (NASDAQ:FLDM)?

Fluidigm Corporation (NASDAQ:FLDM), a life sciences company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $7.81 and falling to the lows of $5.46. … The stock’s ratio of 4.64x is currently trading slightly above its industry peers’ ratio of 3.24x, which means if you buy Fluidigm today, you’d be paying a relatively fair price for it. … And if you believe that Fluidigm should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value.

Simply Wall St -

Is Fluidigm Corporation (NASDAQ:FLDM) A Financially Sound Company?

How does FLDM’s operating cash flow stack up against its debt? … At this stable level of debt, FLDM's cash and short-term investments stands at US$63.14M for investing into the business. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: FLDM’s debt and cash flow levels indicate room for improvement.

Simply Wall St -

Why Did Fluidigm Corporation's' (NASDAQ:FLDM) Insiders Buy Up More Shares?

Fluidigm's insiders have invested 772,529 shares in the small-cap stocks within the past three months. … NasdaqGS:FLDM Insider_trading Mar 27th 18 Over the past three months, more shares have been bought than sold by Fluidigm's' insiders. … Next Steps: Fluidigm’s net buying tells us the stock is in favour with some insiders, which is coherent with the positive growth in expected earnings, on top of a reasonable share price movement around the same time.

Simply Wall St -

Fluidigm Corporation (NASDAQ:FLDM): What Can We Expect From This High Growth Stock?

The most recent earnings release Fluidigm Corporation's (NASDAQ:FLDM) announced in December 2017 signalled company earnings became less negative compared to the previous year's level - great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts view Fluidigm's earnings growth trajectory over the next couple of years and whether the future looks brighter. … Check out our latest analysis for Fluidigm Analysts' outlook for the upcoming year seems buoyant, with earnings becoming less negative, reaching -US$52.18M in 2019. … The slope of this line is the rate of earnings growth, which in this case is 20.99%.

Simply Wall St -

Why You Need To Look At This Factor Before Buying Fluidigm Corporation (NASDAQ:FLDM)

Generally, an investor should consider two types of risk that impact the market value of FLDM. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … With a market cap of US$222.22M, FLDM falls within the small-cap spectrum of stocks, which are found to experience higher relative risk compared to larger companies.

Simply Wall St -

Company Info

Description

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Details
Name: Fluidigm Corporation
FLDM
Exchange: NasdaqGS
Founded: 1999
$855,156,982
69,019,934
Website: http://www.fluidigm.com
Address: Fluidigm Corporation
7000 Shoreline Court,
Suite 100,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FLDM Common Stock Nasdaq Global Select US USD 10. Feb 2011
DB FLB Common Stock Deutsche Boerse AG DE EUR 10. Feb 2011
Number of employees
Current staff
Staff numbers
535
Fluidigm employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 00:11
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/06/17
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.